Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he plans to introduce updated clinical (a) guidance and (b) training for healthcare professionals on the identification and management of Topical Steroid Withdrawal.

Topical corticosteroids are an important and effective treatment for inflammatory skin conditions, including eczema, when used appropriately. It is essential that healthcare professionals are aware of both the benefits and potential risks associated with their use, particularly where treatment is prolonged or involves higher‑potency products.

The Medicines and Healthcare products Regulatory Agency has taken steps to strengthen awareness of topical corticosteroid safety, including public drug safety updates and clearer product information to highlight the risk of adverse effects, including withdrawal reactions, when use has been prolonged or inappropriate. These measures are intended to support informed discussions between clinicians and patients and safer prescribing practice.

Clinical guidance for healthcare professionals is already in place through National Institute for Health and Care Excellence clinical knowledge summaries, which set out best practice on the appropriate potency, duration, and frequency of topical corticosteroid use, and emphasise the importance of regular review. Decisions about diagnosis and management, including recognition of adverse reactions, remain clinical matters for individual healthcare professionals, who are expected to apply this guidance alongside their clinical judgement and the patient’s circumstances.

The Department will keep emerging evidence under review and will work with regulators, the National Health Service, and professional bodies to support ongoing education, promote safe use of medicines, and improve awareness of potential adverse effects among clinicians, including general practitioners and dermatologists.